Navigation Links
ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
Date:2/20/2008

HALIFAX, Feb. 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, announced today the appointment of former senator, Michael Kirby, as the new Board of Directors Chair. Michael Kirby succeeds the late Dr. Warrick Kimmins, who provided exemplary leadership during his tenure and was instrumental in spinning out IVT's novel technology from Dalhousie University.

"I am passionate about advancing health care and am delighted to be part of such a fast-growing biotech company," said former senator Michael Kirby. "IVT has an impressive track record and its patented technology holds tremendous potential to improve vaccines worldwide. "

"Michael Kirby is an internationally respected leader in health care," said Dr. Randal Chase, IVT President and CEO. "His strategic advice will be invaluable, as we enter the next phase of development with the expectation of beginning a new Phase 1 clinical trial in 2009."

The Honourable Michael Kirby has had a distinguished career spanning academia, business, provincial, and federal public service. Most recently, he was appointed, by Prime Minister Stephen Harper, to be the first Chair of the Mental Health Commission of Canada. He also serves on several boards including The Bank of Nova Scotia, Extendicare, Ontario Energy Savings Income Trust, MDC Partners, and Indigo Books and Music.

Senator Kirby was past chair of the Standing Senate Committee on Social Affairs, Science and Technology. He has been a member of the Trilateral Commission, the Council of the International Institute for Applied Systems Analysis, Luxemburg, Austria, and the Club of Rome. He was also a full-time professor in the School of Business Administration and the School of Public Administration at Dalhousie University.

About IVT

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

The company, using its proprietary VacciMax(R) platform, is able to stimulate an earlier, more powerful, long lasting immune response that could provide a new way to treat cancer and infectious diseases.

In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
3. NASA MidSTAR-1 successful technologies may be revolutionary
4. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
5. Neurobiological Technologies Sets Date for Research and Development Day
6. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
7. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
8. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
9. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
10. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
11. Genelabs Technologies to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):